Literature DB >> 2492460

A review of contact dermatitis associated with transdermal therapeutic systems.

M R Holdiness1.   

Abstract

The literature is reviewed for contact dermatitis associated with transdermal therapeutic systems. Clonidine, nitroglycerin, scopolamine, estradiol and testosterone are utilized in such applications, and fentanyl is under investigation. Most cutaneous reactions are limited to localized dermatitis; however, generalized systemic effects may occur. Investigators are reporting skin-related side-effects in up to 50% of patients using transdermal clonidine; however, with the other agents, this is demonstrated much less frequently. Reactivation of the dermatitis via oral medication, following sensitization to the patch, is noted in rare instances.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492460     DOI: 10.1111/j.1600-0536.1989.tb03087.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  5 in total

Review 1.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

2.  Skin irritation in transdermal drug delivery systems: a strategy for its reduction.

Authors:  Koji Kawahara; Kakuji Tojo
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

3.  Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.

Authors:  W Korte; R Morant
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

4.  [Transdermal fentanyl for the treatment of cancer pain.].

Authors:  B Donner; M Zenz; M Tryba; M Strumpf
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

Review 5.  Skin sensitivity and transdermal drug delivery. A review of the problem.

Authors:  A J Carmichael
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.